This trial is comparing two approaches to treatment: a low dose of prednisone, or no prednisone.
Prednisone is a necessary treatment for many patients with GPA but can also be damaging to the body. Researchers want to improve daily life for patients with GPA by having them take less prednisone – but without symptoms of GPA becoming worse, if possible.
By comparing these two treatments (low dose of prednisone, or no prednisone) the researchers hope to gain important insight in to which treatments really work best for GPA patients.
TAPIR allows patients nationwide to participate in research by going online. TAPIR allows many more GPA patients the opportunity to participate in research and to be proactive in their treatment.
The Vasculitis Foundation is the international support group for patients with vasculitis. Through its detailed website, bimonthly newsletter, information packets, symposia, chapters, support groups, international contacts and VF Medical Consultants, the Vasculitis Foundation raises awareness of vasculitis and educates patients, family members and medical professionals about the disease.
TAPIR is being administered by the Vasculitis Clinical Research Consortium (VCRC) and is funded through the National Heart Lung and Blood Institute and National Institutes of Health.
*other conditions may apply. Learn more